Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.

Goga A, Yang D, Tward AD, Morgan DO, Bishop JM.

Nat Med. 2007 Jul;13(7):820-7. Epub 2007 Jun 24.

PMID:
17589519
2.

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.

Kang J, Sergio CM, Sutherland RL, Musgrove EA.

BMC Cancer. 2014 Jan 20;14:32. doi: 10.1186/1471-2407-14-32.

3.

Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.

Chen Y, Tsai YH, Tseng SH.

Surgery. 2013 Jan;153(1):4-16. doi: 10.1016/j.surg.2012.03.030. Epub 2012 Jun 15.

PMID:
22703967
4.

Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.

Cho SJ, Lee SS, Kim YJ, Park BD, Choi JS, Liu L, Ham YM, Moon Kim B, Lee SK.

Cancer Lett. 2010 Jan 28;287(2):196-206. doi: 10.1016/j.canlet.2009.06.011. Epub 2009 Jul 17.

PMID:
19616371
7.

Survivin and escaping in therapy-induced cellular senescence.

Wang Q, Wu PC, Roberson RS, Luk BV, Ivanova I, Chu E, Wu DY.

Int J Cancer. 2011 Apr 1;128(7):1546-58. doi: 10.1002/ijc.25482. Epub 2010 May 25.

8.

Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.

Ng SB, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, Salto-Tellez M, Chng WJ.

J Pathol. 2011 Mar;223(4):496-510. doi: 10.1002/path.2823. Epub 2011 Jan 5.

PMID:
21294123
9.

CDK1 inhibition targets the p53-NOXA-MCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation.

Huskey NE, Guo T, Evason KJ, Momcilovic O, Pardo D, Creasman KJ, Judson RL, Blelloch R, Oakes SA, Hebrok M, Goga A.

Stem Cell Reports. 2015 Mar 10;4(3):374-89. doi: 10.1016/j.stemcr.2015.01.019. Epub 2015 Feb 26.

10.

CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth.

Warfel NA, Dolloff NG, Dicker DT, Malysz J, El-Deiry WS.

Cell Cycle. 2013 Dec 1;12(23):3689-701. doi: 10.4161/cc.26930. Epub 2013 Oct 25.

11.
13.

Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.

Diaz RJ, Golbourn B, Faria C, Picard D, Shih D, Raynaud D, Leadly M, MacKenzie D, Bryant M, Bebenek M, Smith CA, Taylor MD, Huang A, Rutka JT.

Oncotarget. 2015 Feb 20;6(5):3359-74.

15.

Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression.

Weber E, Ravi RK, Knudsen ES, Williams JR, Dillehay LE, Nelkin BD, Kalemkerian GP, Feramisco JR, Mabry M.

Int J Cancer. 1999 Mar 15;80(6):935-43.

16.

Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels.

D'Agnano I, Valentini A, Fornari C, Bucci B, Starace G, Felsani A, Citro G.

Oncogene. 2001 May 17;20(22):2814-25.

17.

Investigation of the cell cycle regulation of cdk3-associated kinase activity and the role of cdk3 in proliferation and transformation.

Braun K, Hölzl G, Soucek T, Geisen C, Möröy T, Hengstschläger M.

Oncogene. 1998 Oct 29;17(17):2259-69.

18.
19.
20.

Lentiviral vector-mediated siRNA knockdown of c-MYC: cell growth inhibition and cell cycle arrest at G2/M phase in Jijoye cells.

Song A, Ye J, Zhang K, Sun L, Zhao Y, Yu H.

Biochem Genet. 2013 Aug;51(7-8):603-17. doi: 10.1007/s10528-013-9590-0. Epub 2013 May 9.

PMID:
23657834

Supplemental Content

Support Center